233 related articles for article (PubMed ID: 32414007)
1. Evading the AAV Immune Response in Mucopolysaccharidoses.
Piechnik M; Sawamoto K; Ohnishi H; Kawamoto N; Ago Y; Tomatsu S
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414007
[TBL] [Abstract][Full Text] [Related]
2. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
[TBL] [Abstract][Full Text] [Related]
5. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
Giles AR; Govindasamy L; Somanathan S; Wilson JM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
[TBL] [Abstract][Full Text] [Related]
6. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
[TBL] [Abstract][Full Text] [Related]
8. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mays LE; Wilson JM
Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
[TBL] [Abstract][Full Text] [Related]
9. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.
Mingozzi F; Meulenberg JJ; Hui DJ; Basner-Tschakarjan E; Hasbrouck NC; Edmonson SA; Hutnick NA; Betts MR; Kastelein JJ; Stroes ES; High KA
Blood; 2009 Sep; 114(10):2077-86. PubMed ID: 19506302
[TBL] [Abstract][Full Text] [Related]
10. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
Rapti K; Grimm D
Front Immunol; 2021; 12():753467. PubMed ID: 34777364
[TBL] [Abstract][Full Text] [Related]
11. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
[TBL] [Abstract][Full Text] [Related]
12. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.
Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS
Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533
[TBL] [Abstract][Full Text] [Related]
13. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
Unzu C; Hervás-Stubbs S; Sampedro A; Mauleón I; Mancheño U; Alfaro C; de Salamanca RE; Benito A; Beattie SG; Petry H; Prieto J; Melero I; Fontanellas A
J Transl Med; 2012 Jun; 10():122. PubMed ID: 22704060
[TBL] [Abstract][Full Text] [Related]
14. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
15. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.
Gorovits B; Azadeh M; Buchlis G; Harrison T; Havert M; Jawa V; Long B; McNally J; Milton M; Nelson R; O'Dell M; Richards K; Vettermann C; Wu B
AAPS J; 2021 Sep; 23(6):108. PubMed ID: 34529177
[TBL] [Abstract][Full Text] [Related]
17. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
Masat E; Pavani G; Mingozzi F
Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
[TBL] [Abstract][Full Text] [Related]
18. CpG-depleted adeno-associated virus vectors evade immune detection.
Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to adeno-associated virus vectors.
Zaiss AK; Muruve DA
Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
